Neue Studien: Europe PMChttps://www.psoriasis-news.de/articles.html/1_articles/page/15/?d=1Neue Studien: Europe PMCdeExosome mediated delivery of Epigallocatechin 3 gallate as a novel approach to alleviate psoriasis symptoms through cytokine and apoptotic pathway modulation.https://www.psoriasis-news.de/articles.html/1_articles/exosome-mediated-delivery-of-epigallocatechin-3-gallate-as-a-novel-approach-to-alleviate-psoriasis-symptoms-through-cytokine-and-apoptotic-pathway-modulation-r204/Weiterlesen

]]>204Sat, 23 Aug 2025 09:18:30 +0000Psychosocial Burden of Visible Psoriasis Vulgaris Lesions: A Case-Control Study on Social Appearance Anxiety and Psychological Well-Beinghttps://www.psoriasis-news.de/articles.html/1_articles/psychosocial-burden-of-visible-psoriasis-vulgaris-lesions-a-case-control-study-on-social-appearance-anxiety-and-psychological-well-being-r203/Background: Psoriasis vulgaris, particularly when manifesting in highly visible regions such as the face and hands, can profoundly impair self-perception and social functioning. Despite a growing interest in psychodermatology, the specific impact of visible psoriatic lesions on social appearance anxiety remains insufficiently explored.

Objective:

To assess the severity of social appearance anxiety in patients with visible psoriasis vulgaris lesions compared to healthy controls, and to examine its associations with general anxiety, depression, perceived disease severity, and dermatology-related quality of life.

Methods:

A cross-sectional case-control study was conducted involving 178 patients diagnosed with psoriasis vulgaris exhibiting visible skin lesions and 196 age- and sex-matched healthy controls. All participants completed the Social Appearance Anxiety Scale (SAAS) and the Hospital Anxiety and Depression Scale (HADS). Patients additionally completed the Dermatology Life Quality Index (DLQI) and a Visual Analog Scale (VAS) to evaluate subjective disease severity. Statistical analyses included group comparisons and Pearson correlations between psychological and clinical parameters.

Results:

SAAS scores were significantly elevated in the patient group (mean = 60.32 ± 8.10) compared to controls (mean = 22.15 ± 9.05; p < 0.001), indicating a large effect size. In psoriasis patients, social appearance anxiety showed a moderate positive correlation with perceived disease severity (r = 0.293, p < 0.01), while correlations with DLQI and depression scores were not statistically significant. General anxiety levels (HADS-A) demonstrated a moderate correlation with SAAS (r = 0.484, p < 0.01).

Conclusion:

Visible lesions in psoriasis vulgaris contribute substantially to social appearance anxiety, independent of general psychopathology. These findings underscore the psychological vulnerability of patients with visible psoriatic involvement and highlight the need for integrated psychosocial interventions as part of comprehensive dermatological care.

Weiterlesen

]]>203Sat, 23 Aug 2025 09:18:30 +0000Traditional Siddha Therapy Using Sivappu Kukkil Thailam (Topical) and Seendhil Chooranam (Oral) for Chronic Plaque Psoriasis: A Single-Patient Case Following the CAse REport (CARE) Guidelineshttps://www.psoriasis-news.de/articles.html/1_articles/traditional-siddha-therapy-using-sivappu-kukkil-thailam-topical-and-seendhil-chooranam-oral-for-chronic-plaque-psoriasis-a-single-patient-case-following-the-case-report-care-guidelines-r202/No abstract supplied.

Weiterlesen

]]>202Sat, 23 Aug 2025 09:18:30 +0000Risk of Serious Infection With Adalimumab in Hidradenitis Suppurativa Compared With Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/risk-of-serious-infection-with-adalimumab-in-hidradenitis-suppurativa-compared-with-psoriasis-r201/Weiterlesen

]]>201Sat, 23 Aug 2025 09:18:30 +0000Scalable Dynamic Scale Proposals for Psoriasis Lesions Detectionhttps://www.psoriasis-news.de/articles.html/1_articles/scalable-dynamic-scale-proposals-for-psoriasis-lesions-detection-r192/Psoriasis is a chronic skin condition characterized by the rapid growth of skin cells, leading to the formation of thick, scaly patches. Detecting these lesions accurately is crucial for early diagnosis and effective treatment. However, the variability in lesion size, shape, and appearance across different skin types presents significant challenges for automated detection systems. Traditional methods often struggle with these variations, leading to reduced accuracy and efficiency. In recent years, convolutional neural networks (CNNs) have emerged as a powerful tool for medical image analysis, particularly in the detection of skin conditions. This paper introduces a novel approach for psoriasis lesion detection using convolutional neural networks (CNNs). The challenge of accurately identifying lesions across various skin types and lesion sizes is addressed by leveraging a scale-aware strategy. In this method, a CNN first estimates the scale distribution of psoriasis lesions within an image by predicting a scale histogram. This histogram serves as a guide for image scaling operations, ensuring that lesions are brought to a uniform scale for subsequent detection. By applying zoom-in and zoom-out transformations based on the predicted scale histogram, the model reduces computational overhead while maintaining high detection accuracy. The proposed approach demonstrates improved efficiency and accuracy in identifying psoriasis lesions, as compared to traditional multi-scale testing techniques, with reduced computational demands. Extensive qualitative and quantitative evaluations on various skin datasets show that the scale-aware strategy significantly enhances lesion detection performance, making it a promising tool for automated psoriasis diagnosis.

Weiterlesen

]]>192Sat, 23 Aug 2025 07:41:28 +0000Prevalence of metabolic syndrome and its components in psoriatic arthritis compared with general population, cutaneous psoriasis, and other inflammatory arthropathies: a meta-analysis.https://www.psoriasis-news.de/articles.html/1_articles/prevalence-of-metabolic-syndrome-and-its-components-in-psoriatic-arthritis-compared-with-general-population-cutaneous-psoriasis-and-other-inflammatory-arthropathies-a-meta-analysis-r191/ObjectivesThrough this meta-analysis, we aim to provide an overview and statistical synthesis of the prevalence of MetS and its components in psoriatic arthritis (PsA) compared to the general populations, patients with cutaneous psoriasis (PsO), and patients with other inflammatory arthropathies.

Method

A search was conducted in Ovid Medline, Web of Science, and Scopus up to February 2024. Original articles investigating the prevalence of MetS in PsA in adults compared to one or more comparison populations were included. Bias risk was assessed by means of a funnel plot. The data was analyzed by means of a random effects model and presented in forest plots.

Results

Of 1526 articles in the original search, 20 relevant were identified. Meta-analyses showed an increased prevalence of MetS in PsA compared to the general population, rheumatoid arthritis (RA), and ankylosing spondylitis (AS) (LogOR 0.93, 0.63, and 1.04, respectively). Meta-analysis showed no difference in the prevalence of MetS in PsA compared to PsO (LogOR 0.15, I2 0.63). Meta-analysis of the prevalence of the different components of MetS in PsA compared to RA showed an increased prevalence of central obesity, hypertriglyceridemia, impaired glucose tolerance, and diabetes mellitus.

Conclusions

PsA was associated with an increased risk of MetS compared to the risk in the general population, in RA and in AS, respectively. This emphasizes the importance of screening for and taking necessary measures to prevent MetS in patients with PsA. Key Points • Patients with PsA have an increased risk of MetS compared to the general population as well as patients with RA or AS. • According to this meta-analysis, the risk of MetS is the same in patients with PsA as in patients with PsO.

Weiterlesen

]]>191Sat, 23 Aug 2025 07:41:28 +0000Checkpoint agonists - immunoregulatory role and its implications in the treatment of psoriasis and psoriatic arthritis.https://www.psoriasis-news.de/articles.html/1_articles/checkpoint-agonists-immunoregulatory-role-and-its-implications-in-the-treatment-of-psoriasis-and-psoriatic-arthritis-r190/Weiterlesen

]]>190Sat, 23 Aug 2025 07:41:28 +0000A Large‐Scale, Retrospective Analysis of Bath‐Psoralen Plus Ultraviolet A Therapy for Psoriasis: A Single‐Center Studyhttps://www.psoriasis-news.de/articles.html/1_articles/a-large%E2%80%90scale-retrospective-analysis-of-bath%E2%80%90psoralen-plus-ultraviolet-a-therapy-for-psoriasis-a-single%E2%80%90center-study-r189/No abstract supplied.

Weiterlesen

]]>189Sat, 23 Aug 2025 07:41:28 +0000Sustained Efficacy and Safety of Tildrakizumab in Psoriasis Vulgaris Despite Multiple Prolonged Treatment Interruptions: A Case Reporthttps://www.psoriasis-news.de/articles.html/1_articles/sustained-efficacy-and-safety-of-tildrakizumab-in-psoriasis-vulgaris-despite-multiple-prolonged-treatment-interruptions-a-case-report-r188/No abstract supplied.

Weiterlesen

]]>188Sat, 23 Aug 2025 07:41:28 +0000TYK2 rs34536443 (P1104A) Variant Suppresses ICAM1-Mediated Inflammation: Insights From Mendelian Randomization and Functional Analyses.https://www.psoriasis-news.de/articles.html/1_articles/tyk2-rs34536443-p1104a-variant-suppresses-icam1-mediated-inflammation-insights-from-mendelian-randomization-and-functional-analyses-r187/BackgroundGenetic susceptibility to psoriasis involves multiple loci, including TYK2 (Tyrosine Kinase 2), which is associated with various autoimmune diseases. However, its specific role and mechanisms in psoriasis remain unclear. This study aimed to identify psoriasis-associated proteins using Summary-based Mendelian Randomization (SMR) and to explore their regulatory mechanisms.

Methods

SMR analysis integrating pQTL data was conducted to identify proteins linked to psoriasis, revealing ICAM1 (Intercellular Adhesion Molecule 1) as a potential pathogenic factor. A key SNP, rs34536443 (P1104A), located in TYK2, was found to regulate ICAM1. To assess its function, THP-1 cells carrying the TYK2-P1104A mutation were generated, and ICAM1 and cytokine expression were analyzed following LPS stimulation. The effect of the TYK2 inhibitor Deucravacitinib was tested in an imiquimod (IMQ)-induced psoriasis mouse model.

Results

SMR identified ICAM1 as a causal protein for psoriasis, regulated by the TYK2 SNP rs34536443. In TYK2-P1104A mutant THP-1 cells, LPS-induced ICAM1 expression was significantly reduced, with ICAM5 unaffected. The mutation also suppressed IL-1β, TNF-α, IL-6, and IL-18 expression, suggesting anti-inflammatory effects. Single-cell RNA-seq revealed enrichment of TYK2, ICAM1, and ICAM5 in dendritic cells and monocytes. In vivo, Deucravacitinib significantly downregulated ICAM1 in the IMQ-induced psoriasis model, with minimal effect on ICAM5.

Conclusion

This study identifies ICAM1 as a key mediator in psoriasis via SMR analysis and implicates the TYK2 SNP rs34536443 in its regulation. The TYK2-P1104A variant attenuates ICAM1 and cytokine expression, and Deucravacitinib downregulates ICAM1 in vivo. These findings provide mechanistic insights into the TYK2-ICAM1 axis and support the therapeutic potential of TYK2 inhibitors for psoriasis.

Weiterlesen

]]>187Sat, 23 Aug 2025 07:41:28 +0000Hydroxytyrosol ameliorates imiquimod-induced psoriasis-like dermatitis by modulating ERK and NF-κB signaling pathways in mice.https://www.psoriasis-news.de/articles.html/1_articles/hydroxytyrosol-ameliorates-imiquimod-induced-psoriasis-like-dermatitis-by-modulating-erk-and-nf-%CE%BAb-signaling-pathways-in-mice-r186/Weiterlesen

]]>186Sat, 23 Aug 2025 07:41:28 +0000Unraveling the Mystery: A Case Report of Erythrodermic Psoriasis as an Adverse Reaction to Wellbutrinhttps://www.psoriasis-news.de/articles.html/1_articles/unraveling-the-mystery-a-case-report-of-erythrodermic-psoriasis-as-an-adverse-reaction-to-wellbutrin-r185/No abstract supplied.

Weiterlesen

]]>185Sat, 23 Aug 2025 07:41:28 +0000A Large-Scale, Retrospective Analysis of Bath-Psoralen Plus Ultraviolet A Therapy for Psoriasis: A Single-Center Study.https://www.psoriasis-news.de/articles.html/1_articles/a-large-scale-retrospective-analysis-of-bath-psoralen-plus-ultraviolet-a-therapy-for-psoriasis-a-single-center-study-r184/Background/purposeWhile biologics and small-molecule inhibitors are first-line systemic treatments for psoriasis, phototherapy remains an alternative for patients unable to access these treatments because of medical or financial constraints. Narrow-band ultraviolet B (NB-UVB) is effective for localized psoriasis but less so for extensive disease. To address this limitation, bathwater delivery of psoralen plus ultraviolet A (bath-PUVA) was introduced in 2004. This study evaluates the efficacy, safety, and patient characteristics associated with bath-PUVA therapy in a large cohort.

Methods

This retrospective analysis included 229 patients (180 males, 49 females) treated with bath-PUVA from 2004 to September 2021. Baseline characteristics and treatment outcomes were assessed using the psoriasis area and severity index (PASI). Statistical analyses examined relationships between treatment outcomes and factors, including baseline PASI, body mass index (BMI), and smoking status.

Results

The mean baseline PASI score was 24.9. Bath-PUVA achieved PASI 75 in 80.4% of patients, PASI 90 in 44.1%, and PASI 100 in 2.6%, with efficacy comparable to biologics. Patients achieving PASI 90 had significantly higher baseline PASI scores (p = 0.005), while the number of irradiations required did not differ (p = 0.692). Higher baseline PASI scores correlated with elevated BMI (p = 0.002), but BMI did not influence improvement rates (p = 0.094). Smokers had significantly higher baseline PASI scores (p = 0.004) compared with non-smokers, yet smoking status did not affect improvement rates (p = 0.862).

Conclusion

Bath-PUVA demonstrates efficacy comparable with biologics for psoriasis, regardless of BMI or smoking status. This analysis supports its use as an effective and accessible treatment option for patients with extensive disease.

Weiterlesen

]]>184Sat, 23 Aug 2025 07:41:28 +0000Arthritis Mutilans: A Devastating Manifestation of Psoriatic Disease Without Dactylitis in a 61-Year-Old Patienthttps://www.psoriasis-news.de/articles.html/1_articles/arthritis-mutilans-a-devastating-manifestation-of-psoriatic-disease-without-dactylitis-in-a-61-year-old-patient-r183/No abstract supplied.

Weiterlesen

]]>183Sat, 23 Aug 2025 07:41:28 +0000Guttate Psoriasis: Another Kid With an Itchy Rash.https://www.psoriasis-news.de/articles.html/1_articles/guttate-psoriasis-another-kid-with-an-itchy-rash-r182/Weiterlesen

]]>182Sun, 10 Aug 2025 12:04:09 +0000MHC-I-opathy: A Unified Concept for the Etiology of Several Major Histocompatibility Complex-Associated Conditions Including Psoriasis and Psoriatic Arthritis.https://www.psoriasis-news.de/articles.html/1_articles/mhc-i-opathy-a-unified-concept-for-the-etiology-of-several-major-histocompatibility-complex-associated-conditions-including-psoriasis-and-psoriatic-arthritis-r181/Weiterlesen

]]>181Sun, 10 Aug 2025 12:04:09 +0000Deciphering difficult-to-treat psoriatic arthritis: insights from an international survey of patients with psoriatic arthritis.https://www.psoriasis-news.de/articles.html/1_articles/deciphering-difficult-to-treat-psoriatic-arthritis-insights-from-an-international-survey-of-patients-with-psoriatic-arthritis-r180/ObjectivesPsoriatic arthritis (PsA) is a heterogeneous inflammatory disease in which a significant proportion of patients remain refractory to existing therapies. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) initiated a project aimed at unravelling the reasons for treatment failures in PsA, culminating in the establishment of definitions for difficult-to-treat PsA (D2T-PsA) and complex-to-manage PsA (C2M-PsA). This study explores patient perspectives on treatment-resistant PsA, incorporating a broader patient perspective into the overarching GRAPPA project.

Methods

A multilingual (10 languages), online survey to explore PsA patients' perspectives on treatment inefficacies was used. It was developed collaboratively by GRAPPA members and patient research partners. It included sections on demographic data, structured questions about treatment failures, and open-ended questions. Data analysis used descriptive statistics and inductive coding of qualitative responses via Dedoose.

Results

Among 570 respondents, most were female (68.8%) and White (72.6%), with an average PsA diagnosis delay of 4.3 years. Key contributors to D2T- and C2M-PsA were persistent joint pain and psoriasis (65.7%), fatigue (52.8%) and medication side effects (41.7%). Ranked by impact, arthritis was the most debilitating symptom. Quality of life concerns were notable, with sleep impairment and reduced life enjoyment being reported by 66.4%. Language differences emerged; for instance, Dutch and Italian respondents prioritized fatigue and daily life impact, respectively.

Conclusion

This is the first international study to highlight patient-driven insights in the management of resistant PsA, emphasizing a multidimensional approach that considers biological and psychosocial factors. These insights will inform the ongoing GRAPPA initiative to standardize definitions for treatment-resistant PsA, ultimately improving patient care.

Weiterlesen

]]>180Sun, 10 Aug 2025 12:04:09 +0000Relative Fat Mass and Psoriasis Risk: Evidence from NHANES 2009-2014.https://www.psoriasis-news.de/articles.html/1_articles/relative-fat-mass-and-psoriasis-risk-evidence-from-nhanes-2009-2014-r179/ObjectiveThis study aims to investigate the relationship between Relative Fat Mass (RFM) and the risk of psoriasis based on data from the US National Health and Nutrition Examination Survey (NHANES) from 2009 to 2014.

Methods

This cross-sectional study included 19,565 adults aged 20 years and older. Psoriasis diagnosis was determined using self-reported questionnaires, and RFM was calculated based on established formulas. Multivariable logistic regression models were used to analyze the association between RFM and psoriasis risk, adjusting for covariates such as age, gender, race, socioeconomic factors, and health behaviors. Nonlinear relationships and potential threshold effects between RFM and psoriasis were assessed using restricted cubic splines.

Results

The analysis revealed a significant positive association between RFM and psoriasis risk. Each 1-unit increase in RFM was associated with a 3% higher likelihood of psoriasis (OR=1.03, 95% CI: 1.02-1.05, P<0.05). The restricted cubic spline analysis showed a nonlinear relationship between RFM and psoriasis risk (P_non-linear=0.028). Subgroup analysis further demonstrated that income level (with lower associations observed among those with a poverty-to-income ratio ≤1.3) moderated the relationship. RFM exhibited moderate predictive performance for psoriasis risk, with an area under the receiver operating characteristic curve (AUC) of 0.549.

Conclusion

RFM is significantly associated with increased psoriasis risk, with a dose-response relationship observed. These findings suggest that RFM may serve as a useful predictor for psoriasis risk and could be incorporated into screening strategies for early detection and prevention.

Weiterlesen

]]>179Sun, 10 Aug 2025 12:04:09 +0000Identification of STAT3 and BIRC5 as anoikis-related biomarkers in psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/identification-of-stat3-and-birc5-as-anoikis-related-biomarkers-in-psoriasis-r178/Weiterlesen

]]>178Sun, 10 Aug 2025 12:04:09 +0000Identification of hub genes for psoriasis and thyroid cancer using bioinformatics analysis.https://www.psoriasis-news.de/articles.html/1_articles/identification-of-hub-genes-for-psoriasis-and-thyroid-cancer-using-bioinformatics-analysis-r177/BackgroundPsoriasis has been associated with an increased risk of various cancers, including thyroid cancer (TC), yet the molecular mechanisms linking these two diseases remain unclear.

Objective

This study aimed to identify and analyze the differentially expressed genes (DEGs) between TC and psoriasis using bioinformatics approaches to explore potential molecular mechanisms and shared pathways. To the best of our knowledge, this is the first bioinformatics-based study to systematically identify and validate shared hub genes between thyroid cancer and psoriasis.

Methods

A TC dataset from the TCGA database and five GEO datasets (GSE35570, GSE13355, GSE14905, GSE53431, and GSE29265) were analyzed, with GSE53431 and GSE29265 serving as validation sets. Differential expression was identified using Xiantao and GEO2R, followed by a series of bioinformatics analyses, including Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Ontology (GO) enrichment, protein-protein interaction (PPI) network construction, transcription factor (TF)-gene interaction, TF-miRNA coregulatory network analysis, and drug molecule prediction.

Results

A total of 79 DEGs associated with TC were identified. Key Enrichr KEGG pathways included a response to the bacterium, NABA MATRISOME ASSOCIATED, negative regulation of cell population proliferation, response to wounding, and HALLMARK KRAS SIGNALING UP. Six hub genes (SERPINA1, S100A9, CCL20, SLPI, LCN2, and CXCL8) were identified from the PPI network, with three genes (SERPINA1, CCL20, and LCN2) showing high diagnostic value for both TC and psoriasis. TF gene and miRNA interactions involving these hub genes and potential drug molecules were also identified.

Conclusion

This study provides insight into potential biomarkers and therapeutic targets relevant to TC and psoriasis, identifying shared molecular pathways and hub genes that may guide future diagnostic and therapeutic approaches for these diseases.

Weiterlesen

]]>177Sun, 10 Aug 2025 12:04:09 +0000Human Dermal Fibroblast-derived Spheroids Demonstrate Efficacious Immune Modulation in a Psoriasis Mouse Modelhttps://www.psoriasis-news.de/articles.html/1_articles/human-dermal-fibroblast-derived-spheroids-demonstrate-efficacious-immune-modulation-in-a-psoriasis-mouse-model-r176/Background: Psoriasis is a chronic inflammatory disease associated with high morbidity and few cases of sustained remission. Innovative immunomodulatory therapies, including fibroblast-based cell therapies, offer promising alternatives. This study investigates the therapeutic potential of human dermal fibroblasts (HDFs) organized into three-dimensional (3D) spheroids in a mouse model of imiquimod (IMQ)-induced psoriasis. Methods HDF spheroids were cultured using Elplasia microcavity plates, and their size, viability, and phenotype were compared with single cells in 2D monolayer cultures. Cellular responses in whole blood and acute inflammatory responses were evaluated at various time points following intravenous injection of HDFs. The therapeutic efficacy of HDF spheroids was assessed using an IMQ-induced psoriasis mouse model, with disease severity scored using the Psoriasis Area and Severity Index (PASI). Optimized HDF spheroids (~150 um, 1x106 cells/mouse) were administered intravenously in a single dose for mild psoriasis or multiple doses for moderate-to-severe psoriasis. The efficacy of HDF spheroids was compared to a pre-clinical monoclonal antibody targeting interleukin 23 (anti-IL-23). Results Spheroid cultures of HDFs showed reduced cell size, enhanced viability, and distinct phenotypic changes compared to monolayer cultures. Intravenous injection of HDF spheroids resulted in less thrombocytopenia and reduced acute inflammatory responses compared to single-cell injection. A single dose of HDF spheroids reduced the severity of mild psoriasis by 35%, while repeated doses resulted in a 36% reduction in moderate-to-severe psoriasis. Single-dose administration normalized blood cell counts, alleviated spleen enlargement, and improved cytokine dysregulation. Although HDF spheroids and anti-IL-23 reduced epidermal thickening and immune cell infiltration, HDF spheroids uniquely inhibited monocyte production and infiltration, a benefit not observed with anti-IL-23. No acute or chronic toxicity was observed. Conclusions HDF spheroids offer comparable therapeutic efficacy to anti-IL-23 in treating psoriasis, with a distinct mechanism involving inhibiting monocyte production and infiltration. Their safety profile and broader immunomodulatory potential support their development as a novel therapeutic strategy for psoriasis and other inflammatory diseases.

Weiterlesen

]]>176Sun, 10 Aug 2025 12:04:09 +0000Composite Outcome Measures for Psoriatic Arthritis: Project Updates 2024.https://www.psoriasis-news.de/articles.html/1_articles/composite-outcome-measures-for-psoriatic-arthritis-project-updates-2024-r175/Weiterlesen

]]>175Sun, 10 Aug 2025 12:04:09 +0000Representation of Psoriasis on the Web for Patients With Skin of Color.https://www.psoriasis-news.de/articles.html/1_articles/representation-of-psoriasis-on-the-web-for-patients-with-skin-of-color-r174/UnlabelledThis study analyzed over 2000 images of psoriasis across major web-based platforms and found a significant underrepresentation of darker skin tones, highlighting a critical gap in dermatologic representation that may contribute to misdiagnoses and health disparities among patients with skin of color.

Weiterlesen

]]>174Sun, 10 Aug 2025 12:04:09 +0000Gender differences in the association between adverse childhood experiences and early onset psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/gender-differences-in-the-association-between-adverse-childhood-experiences-and-early-onset-psoriasis-r173/Weiterlesen

]]>173Sun, 10 Aug 2025 12:04:09 +0000Non-communicable diseases comorbidities negatively impact the treatment outcomes among psoriasis patients: a longitudinal study in Shanghai, China.https://www.psoriasis-news.de/articles.html/1_articles/non-communicable-diseases-comorbidities-negatively-impact-the-treatment-outcomes-among-psoriasis-patients-a-longitudinal-study-in-shanghai-china-r172/BackgroundPsoriasis is frequently associated with non-communicable disease (NCD) comorbidities, prompting interest in how these concurrent conditions may influence psoriasis treatment outcomes.

Objectives

To assess NCD prevalence and their influence on psoriasis treatment outcomes.

Methods

From 2022 to 2024, we recruited psoriasis patients in Shanghai Skin Disease Hospital. Data on demographic features, NCD comorbidities and treatment outcomes at week 4 and week 8 were systematically collected through questionnaire, physical examination, and clinical severity assessment (psoriasis area and severity index [PASI], body surface area [BSA], physician's global assessment [PGA]).

Results

Among 1116 patients, 48.4% had at least one NCD comorbidity. NCD-free patients exhibited higher PASI50 response rates at both week 4 (46.5 vs. 39.1%) and week 8 (72.2 vs. 70.9%). Log binomial regression revealed that NCDs significantly reduced the likelihood of achieving PASI50 at week 4 (relative risk [RR] = 0.84, 95% confidence interval [CI]: 0.73-0.96), with a similar but non-significant trend at week 8 (RR = 0.98, 95% CI: 0.92-1.06).

Conclusion

NCDs negatively impact early treatment outcomes in psoriasis patients. So we propose that dermatologists should integrate systematic NCD management into psoriasis treatment regimen.

Weiterlesen

]]>172Mon, 04 Aug 2025 07:43:04 +0000